Home
News
Create
Screeners
Insights
Bacil Pharma
56.
95
-0.05
(-0.09%)
Market Cap
₹81.73 Cr
PE Ratio
111.76
Industry
Healthcare
Buy
Sell
Company Performance:
1D
-0.09%
1M
-0.19%
6M
+84.54%
1Y
+30.32%
5Y
+644.44%
View Company Insights
Latest news about Bacil Pharma
Bacil Pharma Schedules Board Meeting on May 22, 2026 to Approve Q4 FY26 Audited Financial Results
4 days ago
Bacil Pharma has informed BSE Limited of a Board of Directors meeting to be held on May 22, 2026, to approve audited financial results for the quarter and year ended March 31, 2026. The intimation was filed on May 11, 2026, by Ms. Chaitali Kalpataru Shah, Director and CFO, in compliance with Regulation 29(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting agenda also includes any other business with the permission of the Chairperson.
Bacil Pharma Limited Submits Quarterly Compliance Certificate for Q4FY26
Apr 14, 2026
Bacil Pharma Responds to BSE on Stock Price Movement Clarification
Feb 24, 2026
Norbexi Industries Limited Completely Divests 14.46% Stake in Bacil Pharma Limited
Feb 23, 2026
Bacil Pharma Reports Strong Q3FY26 Turnaround with ₹3.92 Lakh Profit
Feb 13, 2026
More news about Bacil Pharma
30
Dec 25
Khem-Sum Apparels Overseas Ltd. Disposes Complete Stake in Bacil Pharma Limited
Khem-Sum Apparels Overseas Ltd. has completely disposed of its 200-share holding in Bacil Pharma Limited through an off-market sale on December 29, 2025. The promoter group entity's stake has been reduced from 0.001% to zero, representing a complete exit from the pharmaceutical company. The transaction was disclosed under SEBI regulations on December 30, 2025.
29
Dec 25
Bacil Pharma Promoter Suman P. Shah Sells Shares
Bacil Pharma Limited received a substantial disposal disclosure from promoter Suman P. Shah. The promoter sold 500 equity shares through market transactions on December 24, 2025, reducing their shareholding from 0.00% to zero. The company's total equity base of 14,353,000 shares remains unchanged.
19
Dec 25
Bacil Pharma Limited Appoints New Company Secretary Following Recent Resignation
Bacil Pharma Limited announced the proposed appointment of Mr. Dikshant Singh Panwar as Company Secretary, replacing Bhavana Phoolchand Tak who resigned effective December 1, 2025. The new appointee holds membership number ACS42741 and has extensive compliance experience. The appointment requires board confirmation and follows SEBI regulatory requirements.
Bacil Pharma
56.
95
-
0.
05
(-
0.
09
%)
1 Year Returns:
+30.32%
Industry Peers
Sun Pharmaceutical
1,878.20
(+
0.
81
%)
Divis Laboratories
6,760.50
(-
2.
33
%)
Torrent Pharmaceuticals
4,405.70
(+
0.
04
%)
Cipla
1,432.10
(-
0.
32
%)
Dr Reddys Laboratories
1,336.70
(+
2.
54
%)
Lupin
2,276.20
(+
0.
80
%)
Mankind Pharma
2,503.00
(+
1.
66
%)
Zydus Life Science
1,011.70
(+
2.
02
%)
Aurobindo Pharma
1,511.80
(+
0.
06
%)
Laurus Labs
1,323.60
(+
0.
62
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO